Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Operating executive with experience scaling technology and healthcare businesses, known for go-to-market strategy, commercial operations, and growth-stage operational rigor. Chris Lein brings senior leadership across product, sales and corporate development roles at venture-backed companies and PE portfolio firms, advising on revenue scaling, M&A readiness and KPI-driven transformation. Market-facing profile includes board advisory, interim CRO/CBO assignments, and collaboration with growth equity investors on post-investment operational plans.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
Advises growth-oriented investments with a hands-on, operator-led approach focused on commercial value creation in technology and healthcare. Prioritizes capital deployment toward scalable go-to-market, sales enablement and product-led revenue expansion, using KPI-driven roadmaps and short- to mid-term milestones to de-risk execution. Emphasizes M&A readiness and bolt-on consolidation as exit-enhancing levers, aligns management incentives to revenue/ARR and margin inflection, and favors disciplined stage-appropriate capital with operational playbooks to accelerate portfolio growth.
| Trades 570 | Longs Won 437/570 76% | Profit Factor 8.91 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $154,272.61 |
| Average Win $53,360.5 | Best Trade (Oct 14) $2.16M | Sharpe Ratio -10.04 |
| Average Loss -$19,671.25 | Worst Trade (Oct 14) -$998,885 | Z-Score 8.86 (100%) |
| Commissions $0 | Avg. Trade Length 11m 3w 4d | Expectancy $36,319.76 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 5,376 | 4,839 | 4,301 | 3,763 | 3,226 | 2,688 | 2,151 | 1,613 | 1,075 | 538 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 24,584 | $6.16M | $8.42M | - | $2.26M | 36.63% | -0.163% |
ADI Analog Devices, Inc. | 544 | $216,060 | $219,754.24 | - | $3,694.24 | 1.71% | +0.097% |
ADP Automatic Data Processing Inc. | 1,061 | $310,586.17 | $303,955.28 | - | -$6,630.89 | -2.13% | +2.197% |
AGOX Adaptive Alpha Opportunities ETF | 221,209 | $6.23M | $7.28M | - | $1.04M | 16.77% | +0.244% |
ALL Allstate Corporation | 3,307 | $786,780 | $793,746.14 | - | $6,966.14 | 0.89% | +1.63% |
AMAX Adaptive Hedged Multi-Asset Income ETF | 892,491 | $6.96M | $6.67M | - | -$296,947.39 | -4.26% | +0.953% |
AMD Advanced Micro Devices, Inc. | 1,763 | $285,236.02 | $996,518.12 | - | $711,282.1 | 249.37% | -0.978% |
AMZN Amazon.com Inc | 7,605 | $1.66M | $1.94M | - | $278,222.4 | 16.74% | +0.429% |
ARTY iShares Future AI & Tech ETF | 7,010 | $266,725.67 | $509,276.5 | - | $242,550.83 | 90.94% | -1.062% |
AVGO Broadcom Inc. | 1,165 | $272,447.47 | $400,219.44 | - | $127,771.97 | 46.9% | -0.784% |
AXP American Express Company | 597 | $201,935 | $187,613.22 | - | -$14,321.78 | -7.09% | +2.381% |
BP BP p.l.c. Sponsored ADR | 16,876 | $501,299.2 | $815,870.22 | - | $314,571.02 | 62.75% | -0.953% |
BRK-B Berkshire Hathaway Inc. | 6,658 | $3.02M | $3.51M | - | $494,388.63 | 16.38% | +0.22% |
BYLD iShares Yield Optimized Bond ETF | 50,093 | $1.11M | $1.09M | - | -$22,048.24 | -1.99% | +0.532% |
CAT Caterpillar Inc. | 665 | $241,235.26 | $490,341.06 | - | $249,105.8 | 103.26% | -1.552% |
CLSE Convergence Long/Short Equity Fund | 5,940 | $202,762 | $202,138.2 | - | -$623.8 | -0.31% | -0.787% |
CSX CSX Corporation | 20,520 | $662,176.95 | $997,682.4 | - | $335,505.45 | 50.67% | +0.704% |
CVX Chevron Corporation | 2,632 | $386,847.75 | $574,460.29 | - | $187,612.54 | 48.5% | -1.702% |
DAL Delta Air Lines, Inc. | 4,384 | $245,763.68 | $341,033.55 | - | $95,269.87 | 38.76% | +1.773% |
DBE Invesco DB Energy Fund | 16,967 | $316,680.52 | $659,337.62 | - | $342,657.1 | 108.2% | -0.487% |